{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:53:31Z","timestamp":1794020011966,"version":"4.8.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T00:00:00Z","timestamp":1410998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00296-014-3132-x","type":"journal-article","created":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T18:11:27Z","timestamp":1410977487000},"page":"767-772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Continuous effect with long-term safety in zoledronic acid therapy for polyostotic fibrous dysplasia with severe bone destruction"],"prefix":"10.1007","volume":"35","author":[{"given":"Di","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suqing","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,18]]},"reference":[{"key":"3132_CR1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/PLMI.S24866","volume":"3","author":"H Mohan","year":"2011","unstructured":"Mohan H, Mittal P, Mundi I, Kumar S (2011) Fibrous dysplasia of bone: a clinicopathologic review. Pathol Lab Med Int 3:31\u201342","journal-title":"Pathol Lab Med Int"},{"key":"3132_CR2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bone.2004.03.004","volume":"35","author":"RD Chapurlat","year":"2004","unstructured":"Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ (2004) Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 35:235\u2013242","journal-title":"Bone"},{"issue":"7 Suppl 1","key":"3132_CR3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1750-1172-7-S1-S3","volume":"24","author":"RD Chapurlat","year":"2012","unstructured":"Chapurlat RD, Gensburger D, Jimenez-Andrade JM, Ghilardi JR, Kelly M et al (2012) Pathophysiology and medical treatment of pain in fibrous dysplasia of bone. Orphanet J Rare Dis 24(7 Suppl 1):S3","journal-title":"Orphanet J Rare Dis"},{"key":"3132_CR4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ddr.10071","volume":"55","author":"JR Green","year":"2002","unstructured":"Green JR, Rogers MJ (2002) Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 55:210\u2013224","journal-title":"Drug Dev Res"},{"key":"3132_CR5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.4158\/EP10136.CR","volume":"16","author":"LS Mansoori","year":"2010","unstructured":"Mansoori LS, Catel CP, Rothman MS (2010) Bisphosphonate treatment in polyostotic fibrous dysplasia of the cranium: case report and literature review. Endocr Pract 16:851\u2013854","journal-title":"Endocr Pract"},{"issue":"Suppl 2","key":"3132_CR6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1359\/jbmr.06s222","volume":"21","author":"RD Chapurlat","year":"2006","unstructured":"Chapurlat RD (2006) Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res 21(Suppl 2):114\u2013119","journal-title":"J Bone Miner Res"},{"issue":"Suppl 4","key":"3132_CR7","first-page":"434","volume":"4","author":"EA Imel","year":"2007","unstructured":"Imel EA, Econs MJ (2007) Fibrous dysplasia, phosphate wasting and fibroblast growth factor 23. Pediatr Endocrinol Rev 4(Suppl 4):434\u2013439","journal-title":"Pediatr Endocrinol Rev"},{"key":"3132_CR8","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1359\/jbmr.2001.16.5.806","volume":"16","author":"MT Collins","year":"2001","unstructured":"Collins MT, Chebli C, Jones J, Kushner H, Consugar M et al (2001) Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. J Bone Miner Res 16:806\u2013813","journal-title":"J Bone Miner Res"},{"key":"3132_CR9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003086-200101000-00003","volume":"382","author":"JM Lane","year":"2001","unstructured":"Lane JM, Khan SN, O\u2019Connor WJ, Nydick M, Hommen JP et al (2001) Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Relat Res 382:6\u201312","journal-title":"Clin Orthop Relat Res"},{"key":"3132_CR10","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","volume":"349","author":"J Beitz","year":"2003","unstructured":"Beitz J, Ibrahim A, Scher N, Williams G (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349:1676\u20131679","journal-title":"N Engl J Med"},{"key":"3132_CR11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","volume":"64","author":"GS Markowitz","year":"2003","unstructured":"Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J et al (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281\u2013289","journal-title":"Kidney Int"},{"key":"3132_CR12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4103\/0973-1482.126471","volume":"9","author":"PH Chiang","year":"2013","unstructured":"Chiang PH, Wang HC, Lai YL, Chen SC, Yen-Hwa W et al (2013) Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan. J Cancer Res Ther 9:653\u2013659","journal-title":"J Cancer Res Ther"},{"key":"3132_CR13","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1210\/jc.2012-1027","volume":"97","author":"S Khosla","year":"2012","unstructured":"Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD et al (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97:2272\u20132282","journal-title":"J Clin Endocrinol Metab"},{"key":"3132_CR14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/1756-185X.12263","volume":"17","author":"S Metyas","year":"2014","unstructured":"Metyas S, Ibrahim M, Solyman J, Yeter KC, Arkfeld DG (2014) Giant cell arteritis with visual loss following zoledronic acid infusion. Int J Rheum Dis 17:113\u2013115","journal-title":"Int J Rheum Dis"},{"key":"3132_CR15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s00223-013-9829-0","volume":"94","author":"MD Thomsen","year":"2014","unstructured":"Thomsen MD, Rejnmark L (2014) Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia. Calcif Tissue Int 94:384\u2013395. doi: 10.1007\/s00223-013-9829-0","journal-title":"Calcif Tissue Int"},{"key":"3132_CR16","doi-asserted-by":"crossref","unstructured":"Boyce AM, Kelly MH, Brillante BA, Kushner H, Wientroub SJ et al (2014) A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone. J Clin Endocrinol Metab. doi: 10.1210\/jc.2014-1371","DOI":"10.1210\/jc.2014-1371"},{"key":"3132_CR17","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","volume":"353","author":"IR Reid","year":"2005","unstructured":"Reid IR, Miller P, Lyles K, Fraser W, Brown JP et al (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2019s disease. N Engl J Med 353:898\u2013908","journal-title":"N Engl J Med"},{"key":"3132_CR18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1423-0127-21-10","volume":"21","author":"M Tsubaki","year":"2014","unstructured":"Tsubaki M, Komai M, Itoh T, Imano M, Sakamoto K et al (2014) Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1\/2 and Akt activation. J Biomed Sci 21:10","journal-title":"J Biomed Sci"},{"key":"3132_CR19","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1359\/jbmr.080312","volume":"23","author":"MJ Bolland","year":"2008","unstructured":"Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG et al (2008) Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. J Bone Miner Res 23:1304\u20131308","journal-title":"J Bone Miner Res"},{"key":"3132_CR20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/jbmr.2009","volume":"29","author":"A Grey","year":"2014","unstructured":"Grey A, Bolland M, Mihov B, Wong S, Horne A et al (2014) Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial. J Bone Miner Res 29:166\u2013172","journal-title":"J Bone Miner Res"},{"key":"3132_CR21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/TCRM.S3768","volume":"5","author":"RD Chapurlat","year":"2009","unstructured":"Chapurlat RD (2009) Treatment of osteoporosis with annual IV zoledronic acid: effects on hip fracture. Ther Clin Risk Manag 5:169\u2013175","journal-title":"Ther Clin Risk Manag"},{"key":"3132_CR22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","volume":"26","author":"F Cosman","year":"2011","unstructured":"Cosman F, Eriksen EF, Recknor C, Miller PD, Gua\u00f1abens N et al (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 26:503\u2013511","journal-title":"J Bone Miner Res"},{"key":"3132_CR23","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00198-013-2585-1","volume":"25","author":"K Ganda","year":"2014","unstructured":"Ganda K, Seibel MJ (2014) Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases. Osteoporos Int 25:777\u2013782","journal-title":"Osteoporos Int"},{"key":"3132_CR24","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1210\/jc.2012-1262","volume":"97","author":"DW Dempster","year":"2012","unstructured":"Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA et al (2012) Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab 97:2799\u20132808","journal-title":"J Clin Endocrinol Metab"},{"key":"3132_CR25","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1359\/jbmr.091036","volume":"25","author":"S Piersanti","year":"2010","unstructured":"Piersanti S, Remoli C, Saggio I, Funari A, Michienzi S et al (2010) Transfer, analysis, and reversion of the fibrous dysplasia cellular phenotype in human skeletal progenitors. J Bone Miner Res 25:1103\u20131116","journal-title":"J Bone Miner Res"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-014-3132-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-014-3132-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-014-3132-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T16:42:42Z","timestamp":1717346562000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-014-3132-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,18]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["3132"],"URL":"https:\/\/doi.org\/10.1007\/s00296-014-3132-x","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,18]]}}}